<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03580525</url>
  </required_header>
  <id_info>
    <org_study_id>HIC: 2000023289</org_study_id>
    <nct_id>NCT03580525</nct_id>
  </id_info>
  <brief_title>Nicotine Delivery Rate and Its Abuse Potential: Impact of Menthol</brief_title>
  <official_title>Nicotine Delivery Rate and Its Abuse Potential: Impact of Menthol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A placebo-controlled study to enroll male and female tobacco smokers menthol (n=35) and
      non-menthol (n=35) who will participate in five experimental sessions. subjects will be given
      an IV infusion of either saline or 1 mg nicotine at rapid, moderate or slow infusion rates
      (nicotine at 0.24,0.096, 0.048 and 0.024, mcg per kg body weight per sec).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A placebo-controlled study that will enroll male and female tobacco smokers menthol (n=35)
      and non-menthol (n=35) to participate in five experimental sessions. During the experimental
      session, subjects will be given an IV infusion of either saline or 1 mg nicotine at rapid,
      moderate or slow infusion rates (nicotine at 0.24,0.096, 0.048 and 0.024, mcg per kg body
      weight per sec). The infusion conditions for each experimental session will be determined in
      random order. Aim 1 is to establish a dose-effect curve for positive subjective effects (drug
      liking and good drug effects) and alleviation of smoking urges, as a function of nicotine
      delivery rate in menthol and non-menthol cigarette preferring smokers Aim 2 is to establish a
      dose-effect curve positive subjective effects and alleviation of smoking urges as a function
      of nicotine delivery rate. Aim 3 is to establish a dose-effect curve for nicotine's effect to
      alleviate symptoms of nicotine withdrawal in abstinent smokers as a function of nicotine
      delivery rate. Aim 4 is to establish a dose-effect curve for nicotine's acute cardiovascular
      health effects. Data from this project will help to establish benchmark values for nicotine's
      threshold effects that will guide policies on the nicotine yield of tobacco products.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Suspended due to Covid-19
  </why_stopped>
  <start_date type="Actual">February 14, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Single blind, placebo-controlled, mixed-design with nicotine delivery as a within-subjects factor.</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Participant will not know nicotine dose or rate of infusion.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Changes on items of the Drug Effects Questionnaire (DEQ)</measure>
    <time_frame>up to 60 minutes post infusion</time_frame>
    <description>The peak change in the intensity of subjective effects as measured by the DEQ: Drug effects questionnaire; Eleven questions with a minimum score of 0 to a maximum score of 100.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Nicotine Dependence</condition>
  <arm_group>
    <arm_group_label>nicotine saline infusion 0.00mcg/kg/s</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.00 mcg/kg/s The day order will be randomized per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nicotine infusion 0.24mcg/kg/s</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.24mcg/kg/s The day order will be randomized per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nicotine infusion 0.096mcg/kg/s</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.096mcg/kg/s The day order will be randomized per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nicotine infusion 0.048mcg/kg/s</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.048mcg/kg/s The day order will be randomized per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nicotine infusion 0.024mcg/kg/s</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.048mcg/kg/s The day order will be randomized per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine saline infusion 0.00mcg/kg/s</intervention_name>
    <description>saline 0.00mcg/kg/s</description>
    <arm_group_label>nicotine saline infusion 0.00mcg/kg/s</arm_group_label>
    <other_name>nicotine infusion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine infusion 0.24mcg/kg/s</intervention_name>
    <description>nicotine 0.24mcg/kg/s</description>
    <arm_group_label>nicotine infusion 0.24mcg/kg/s</arm_group_label>
    <other_name>nicotine infusion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine infusion 0.096mcg/kg/s</intervention_name>
    <description>nicotine 0.096mcg/kg/s</description>
    <arm_group_label>nicotine infusion 0.096mcg/kg/s</arm_group_label>
    <other_name>nicotine infusion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine infusion 0.048 mcg/kg/s</intervention_name>
    <description>nicotine 0.048mcg/kg/s</description>
    <arm_group_label>nicotine infusion 0.048mcg/kg/s</arm_group_label>
    <other_name>nicotine infusion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine infusion 0.024mcg/kg/s</intervention_name>
    <description>nicotine 0.024mcg/kg/s</description>
    <arm_group_label>nicotine infusion 0.024mcg/kg/s</arm_group_label>
    <other_name>nicotine infusion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Female and male smokers, aged 18 to 35 years, who have been smoking tobacco cigarettes
             for at least a year

          -  Smoke â‰¥ 5 and less than 20 cigarettes per day;

          -  Urine cotinine levels &gt; 100 ng/mL consistent with nicotine intake of an active smoker
             (23)

          -  Not seeking treatment at the time of the study for nicotine dependence;

          -  In good health as verified by medical history, screening examination, and screening
             laboratory tests

          -  For women, not pregnant as determined by pregnancy screening, nor breast feeding, and
             using acceptable birth control methods.

        Exclusion criteria:

          -  History of major medical or psychiatric disorders that the physician investigator
             deems as contraindicated for the subject to be in the study

          -  Regular use of psychotropic medication (antidepressants, antipsychotics, or
             anxiolytics)

          -  Current alcohol or substance dependence for any other recreational or prescription
             drugs other than nicotine

          -  Use of e-cigarettes more than 10 days in the past 30 days

          -  Urine drug screening indicating recent illicit drugs use (with the exception of
             marijuana).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mehmet Sofuoglu, M.D.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor of Psychiatry</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Veterans Affairs Hospital</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>June 26, 2018</study_first_submitted>
  <study_first_submitted_qc>June 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2018</study_first_posted>
  <last_update_submitted>April 8, 2020</last_update_submitted>
  <last_update_submitted_qc>April 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Mehmet Sofuoglu</investigator_full_name>
    <investigator_title>Professor of Psychiatry</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

